Finanzen von ARS Pharmaceuticals Inc (SPRY)SPRYARS Pharmaceuticals Inc

Evaluating the bottom line, ARS Pharmaceuticals, Inc. maintains a gross margin of 61.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -182.62%, while the net margin is -185.21%. These profitability ratios, combined with a Return on Equity (ROE) of -210.35%, provide a clear picture of how effectively SPRY converts its operational activities into shareholder value.

In the context of the broader market, SPRY competes directly with industry leaders such as EIKN and INDP. With a market capitalization of $426.63M, it holds a significant position in the sector. When comparing efficiency, SPRY's gross margin of 61.83% stands against EIKN's N/A and INDP's N/A. Such benchmarking helps identify whether ARS Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a total revenue of $33.7 million for Q2 2026, a 114% increase from Q2 2025, but has been experiencing significant net losses, with a net income of -62.3 million in Q2 2026.